Literature DB >> 26807564

Comparison of Serum Human Epididymis Protein 4 and Carbohydrate Antigen 125 as Markers in Endometrial Cancer: A Meta-Analysis.

Lingli Hu1, Shizheng Du, Wanhua Guo, Dezhu Chen, Ying Li.   

Abstract

OBJECTIVES: For patients with endometrial cancer (EC), the screening value of serum human epididymis protein 4 (HE4) remains controversial. We performed meta-analyses to compare the screening accuracy of serum HE4 and carbohydrate antigen 125 (CA125) for EC.
MATERIALS AND METHODS: A search of diagnostic test studies was performed in 5 English databases: Pubmed, Cochrane Library, Web of Science, Science Direct, and Elton Bryan Stephens Co or EBSCO; and 2 Chinese databases including China National Knowledge Infrastructure or CNKI and VIP (Weipu Database), from their inception dates to early July 2015. Two reviewers independently selected trials, conducted critical appraisal, and extracted data. Meta-analyses were performed to compare the screening accuracy between HE4 and CA125. Summary receiver operating characteristic curve and the area under the summary receiver operating characteristic curve were performed. Subgroup analysis, meta-regression, sensitivity analysis, and Egger plot and the Egger test were also conducted.
RESULTS: Twenty-one studies were identified, and the methodological quality was generally fair. Meta-analyses revealed that the pooled sensitivity, specificity, positive likelihood ratio, negative likelihood ratio, and diagnostic odds ratios for HE4 in screening EC were 0.56, 0.89, 6.41, 0.49, and 14.82, respectively, whereas the pooled sensitivity, specificity, positive likelihood ratio, negative likelihood ratio, and diagnostic odds ratio for CA125 in screening EC were 0.32, 0.81, 2.15, 0.83, and 2.74, respectively. The areas under the summary receiver operating characteristic curves for HE4 and CA125 were 0.7778 and 0.5474, respectively.
CONCLUSIONS: This study indicates that serum HE4 may be superior to CA125 in screening accuracy of EC. This conclusion has to be interpreted cautiously owing to high heterogeneity and some limitations.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26807564     DOI: 10.1097/IGC.0000000000000621

Source DB:  PubMed          Journal:  Int J Gynecol Cancer        ISSN: 1048-891X            Impact factor:   3.437


  6 in total

Review 1.  Circulating biomarkers in epithelial ovarian cancer diagnosis: from present to future perspective.

Authors:  Martina Montagnana; Marco Benati; Elisa Danese
Journal:  Ann Transl Med       Date:  2017-07

2.  The clinical significance of DJ-1 and HE4 in patients with endometrial cancer.

Authors:  Marco Benati; Martina Montagnana; Elisa Danese; Elisa Paviati; Silvia Giudici; Orazio Ruzzenente; Massimo Franchi; Giuseppe Lippi
Journal:  J Clin Lab Anal       Date:  2017-04-04       Impact factor: 2.352

3.  The Application Value of Serum HE4 in the Diagnosis of Lung Cancer.

Authors:  Yuhui Wang; Zhenming Wang; Yansheng Ding; Fengqiang Sun; Xiaomei Ding
Journal:  Asian Pac J Cancer Prev       Date:  2019-08-01

Review 4.  The Role of Human Epididymis Protein 4 in the Diagnosis and Prognosis of Diseases: An Umbrella Review of Systematic Reviews and Meta-Analyses of Observational Studies.

Authors:  Ming-Li Sun; Zhi-Yong Yang; Qi-Jun Wu; Yi-Zi Li; Xin-Yu Li; Fang-Hua Liu; Yi-Fan Wei; Zhao-Yan Wen; Bei Lin; Ting-Ting Gong
Journal:  Front Med (Lausanne)       Date:  2022-03-24

5.  Clinical importance of serum HE4 and MMP2 levels in endometrial cancer patients.

Authors:  Aneta Cymbaluk-Płoska; Anita Chudecka-Głaz; Ewa Pius-Sadowska; Agnieszka Sompolska-Rzechuła; Bogusław Machaliński; Anna Surowiec; Janusz Menkiszak
Journal:  Onco Targets Ther       Date:  2017-06-27       Impact factor: 4.147

6.  Clinical significance of pretreatment serum levels of VEGF and its receptors, IL- 8, and their prognostic value in type I and II endometrial cancer patients.

Authors:  Beata Kotowicz; Malgorzata Fuksiewicz; Joanna Jonska-Gmyrek; Alicja Berezowska; Jakub Radziszewski; Mariusz Bidzinski; Maria Kowalska
Journal:  PLoS One       Date:  2017-10-09       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.